Replies to post #29692 on Radient Pharmaceuticals Corporation fka RXPC

[livinginsv]

2016 is getting closer every day.

[guardiangel]

Radient Restructured By A Planned Reverse Merger

August 10, 2015

Here is the proof that the New Generation DR-70 has been Developed..Korea was already approved for the selling of the OLD generation DR-70 you understand. Now Korea is approving the new generation DR-70 this year and China in 2017.


Uni Pharma has noticed the medical advancement for cancer monitoring and therapies in Asia. The economic growth and increasing ratio of health related consumptions to GDP also encourages Uni Pharma takes its distributionship of DR-70®(in Taiwan to the next level and establishes a manufacturing site for Asia region. This allows Uni pharma to ensure the supply chain and cold chain quality of DR-70®(test to cover Asia-Pacific countries. Up to date, Uni Pharma has already exported DR-70®(to India and Turkey. Other countries like Korea, China are under regulatory filing and expect to receive approval by Q4 2015 and 2017, respectively.

AMDL Diagnostics and Uni-Pharma agreement still in force..The dis tractors think different..That is because they don't know how to read and interpret agreements you understand..Also the aussies web site can not be found on foreign servers, if so the person who posted that silly premise would have posted the changes by paste and copy instead of making up the differences you understand..lol OK?


UniPharma Offers Advanced Cancer Diagnostic Tests: DR-70 ELISA test and Cervi-M DNA Methylation Test

http://www.bioclub.com.tw/en/mediaExhibitorNewsDetail.asp?id=551



Uni Pharma Co. Ltd ( Uni Pharma here after) debuts Cervi-M DNA Methylation test ( Cervi-M here after) for Cervical Cancer in BioTaiwan 2015. Cervi-M is developed by iStat and distributed by Uni Pharma since September 2015. Cervi-M received TFDA approval in 2013 under GMP and ISO17025. This test has granted patents in US , Taiwan and China. Other patents in 16 different countries in EU, Brazil, Japan and Canada..etc are pending.



Cervi-M is a test detecting DNA methylation, particularly PAX 1 gene. Simply using the cells from Pap smear sample residual and amply cell signal by real-time PCR ( Polymerase Chain Reaction) instrument to detect the methylated DNA. After over a decade’s research effort by Dr. Hung-Cheng Lai, Deputy Superintendent of Shuang-Ho Hospital and his team, Cervi-M is finally available for clinical use. It is proven that combing with Pap Smear, Cervi-M test can reach 93% sensitivity as a great tool for Cervical Cancer detection. Currently Cervi-M is available in 3 major medical centers in Taiwan and will continue expand its footprint in more hospitals in Taiwan and around the world.



Since 2013, Uni Pharma successfully in-licensed DR-70®ELISA Test from USA and co-developed with Pharmigene. With great effort from Uni Pharma and Pharmigene, Taiwan-made DR-70®test passed TFDA and SGS audit and proudly received GMP and ISO 13485 certificate in March 2014. Furthermore, DR-70®receives Taiwan FDA marketing approval in August 2014 and CE certificate in September 2014.



DR-70®( licensed by Uni Pharma is approved by US FDA for colorectal cancer monitoring in 2008 and it is the only tumor marker approved for colorectal cancer monitoring by FDA since 1985. Serial testing using the DR-70®(by measure the concentration of Fibrin/fibrinogen degradation products, FDP) is to use as an aid in monitoring disease progression and treatment evaluation. Through its high accuracy, DR-70®(has helped numerous clinical physicians and their patients worldwide.



Uni Pharma has noticed the medical advancement for cancer monitoring and therapies in Asia. The economic growth and increasing ratio of health related consumptions to GDP also encourages Uni Pharma takes its distributionship of DR-70®(in Taiwan to the next level and establishes a manufacturing site for Asia region. This allows Uni pharma to ensure the supply chain and cold chain quality of DR-70®(test to cover Asia-Pacific countries. Up to date, Uni Pharma has already exported DR-70®(to India and Turkey. Other countries like Korea, China are under regulatory filing and expect to receive approval by Q4 2015 and 2017, respectively.



Moreover, Uni Pharma continues to develop new products in order to have a complete pipeline for oncology diagnosis, oncology drug monitoring test and neurology diagnosis. Early this year, Uni Pharma has entered exclusive distribution right of MyCare with Saladax ( U.S company ), MyCare is a collective term for three companion diagnostic tests that can help oncologists to optimize the best drug dosage for cancer patients. It is also a great milestone for Uni Pharma to enter the new era of personalized medicine. Moreover, Uni Pharma recently signed an exclusive distribution agreement with Hakuzo Medical Corporation, located in Osaka, Japan to make their products available in Taiwan.



Uni Pharma was founded in 1998 and experienced in registration, marketing and selling of biologics, medical devices, and diagnostic related products. Uni Pharma mainly supplies to medical center and district hospitals in Taiwan. Uni Pharma has its headquarter in Taipei with more than 30 employees and deploys sales channels in every region in Taiwan. With strong base in Taiwan, Uni Pharma expands its business scope to Asia countries and beyond.




http://www.bioclub.com.tw/en/mediaExhibitorNewsDetail.asp?id=551

Who will Provista Diagnostics use as a distributor and partner to sell Videssa worldwide? Who owns the 90 per cent of RXPC Common shares besides the lenders? One of those questions is still a mystery..Most of the shares were purchased before, during, and after the GCDX and Radient agreement you understand...

http://www.saladax.com/mycare/products/my5fu/



Moreover, Uni Pharma continues to develop new products in order to have a complete pipeline for oncology diagnosis, oncology drug monitoring test and neurology diagnosis. Early this year, Uni Pharma has entered exclusive distribution right of MyCare with Saladax ( U.S company ), MyCare is a collective term for three companion diagnostic tests that can help oncologists to optimize the best drug dosage for cancer patients.

* MyCare is currently not available in the U.S.

http://www.saladax.com/mycare/products/my5fu/

http://www.saladax.com/mycare-products/


Breast Cancer hmmmmmm

http://www.saladax.com/about-saladax-biomedical-inc/



It is also a great milestone for Uni Pharma to enter the new era of personalized medicine. Moreover, Uni Pharma recently signed an exclusive distribution agreement with Hakuzo Medical Corporation, located in Osaka, Japan to make their products available in Taiwan.

http://www.hakuzo.co.jp/eng/index.php

http://www.hakuzo.com/eng/company/



Uni Pharma was founded in 1998 and experienced in registration, marketing and selling of biologics, medical devices, and diagnostic related products. Uni Pharma mainly supplies to medical center and district hospitals in Taiwan. Uni Pharma has its headquarter in Taipei with more than 30 employees and deploys sales channels in every region in Taiwan. With strong base in Taiwan, Uni Pharma expands its business scope to Asia countries and beyond.

http://www.bioclub.com.tw/en/mediaExhibitorNewsDetail.asp?id=551

*********************************************************************************************************

Radient Restructured By A Planned Reverse Merger

August 8, 2015

dc and JIm..We are getting closer to the planned reverse merger between Provista Diagnostics and Radient Shell according to the 2010 LOI..Look for Uni-Pharma partnership to promote PDX Cancer tests worldwide.....

The monies will be utilized for key management hires. Who Can It Be Now? Not the Aussies you understand.. E.F. Wolf

From August 4,2015 offering
key management hires

From March 17,2015 offering..

key clinical hires



August 4, 2015: Provista Diagnostics, Inc., a privately held molecular diagnostics company headquartered in New York, today announced the closing of $6.0 Million of Series A-2 Preferred financing. All of the funds come from existing investors exercising warrants from a previous financing round. The proceeds will be used for continued commercial development, prospective clinical trials, key management hires and general corporate purposes.

NEW YORK, NY – March 17, 2015: Provista Diagnostics, Inc., a privately-held molecular diagnostics company headquartered in New York, today announced the closing of $3.9 Million of Series A-1 Preferred financing. All of the funds come from existing investors exercising warrants from a previous financing round. The proceeds will be used for continued commercial development, prospective clinical trials, key clinical hires and general corporate purposes.

http://www.provistadx.com/home/news-and-events

http://provistadx.com/

2015-08-05 TEAS STATEMENT OF USE RECEIVED

https://trademarks.justia.com/863/83/videssa-86383350.html




*******************************************************************************

This is All The DD and Rebuttals with ALL of the facts and findings you will ever need to know in ONE Quick Link and Page;

Why Radient Pharmaceuticals Public Shell will be utilized for The Proposed LOI of 2010 to reverse Merge with Provista Diagnostics.


Due Diligence: Analysis on Facts and Findings.


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113814338




Past posts and Developments July 15.2015 Through August 7, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116001106

From JULY 14, 2015 and past posts

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=115395738